The aim of the study was to investigate effects of Palosuran in renovascular hypertension and induced cardiac and renal complications in rats. Hypertension, as one of the most common chronic diseases, produces a substantial morbidity and mortality rate. Uncontrolled hypertension increases the risk of stroke, coronary artery and kidney diseases. Despite the wide array of drugs currently available for treating high blood pressure (BP), it is still difficult to avoid the manifestations of existing antihypertensive drug side-effects that reduce treatment efficacy. Studies have shown that in hypertensive rats, Palosuran reveals a hypotensive effect, decreases the workload on the myocardium, and reduces the risk of cardiac and renal complications. It should also be mentioned that the impact of treatment is better expressed at the early stage of hypertension. According the study results, excessive secretion of cyclic vasoactive neuropeptide urotensin-2 (U-II), with strong vasoconstrictor properties and up-regulation of UT-II receptors (UTR) identified in several pathological states, especially hypertension, increases the interest of researchers investigating effects of U-II/UTR antagonists as an attractive target in hypertensive disease, cardiovascular and renal system pathology. Effect of the Palosuran, UTR antagonist (10 mg/kg, i.p., daily for 4 weeks) was studied on 32 male Wistar rats with renovascular hypertension (RH). BP was measured non-invasively (BP measurement system "Systola"). The renal functional markers -serum creatinine (SC) was measured spectrophotometrically (Cobas-Roshe C111) and plasma renin (PR) by ELISA (HumaStar HS) method. Heart and renal tissue samples for THE CAUCASUS ECONOMIC & SOCIAL ANALYSIS JOURNAL OF SOUTHERN CAUCASUS (11) --morphological investigations were stained with hematoxylin-eosin (H&E). In Palosuran-treated rats (PTR) with RH on the 8th weeks of hypertension, mean arterial pressure (MAP) was reduced by 32% (p<.001), PRby 33% (р<.01) and SCby 26% (p<.05). On the 12th week of hypertension, BP was decreased by 23% (p<.02), PR-by 24% (р<.01), and SCby 9,4% (p<.01) compared to control. In PTR, the left ventricular size (LVS) was 1,07 mm, right -0,19 mm (within the norm). Slightly expressed hypertrophy was observed by the 12th week of hypertension. LVS was 1,12 mm and right -0,21 mm. In PTR renal tissue, by 12th week of hypertension, tubular dilatation was detected without glomerular hyperemia and RBC diapedesis. Palosuran reveals a hypotensive effect in RH rats, improves renal functional markers, decreases the workload on the myocardium, and reduces the risk of cardiac and renal complications. The impact of treatment is better expressed at the early stage of hypertension.